The growth of these products comes from strong patient demand. These two long-acting medicines contributed more than 50% of the total HIV growth and now account for 20% of HIV sales. In 2025, GSK ...
Smith reminds investors that class action lawsuits ... and/or misleading statements and/or failed to disclose that: (1) GSK was fully aware of the source of NDMA and had been for nearly 40 years ...
1,2 Tony Wood, Chief Scientific Officer, GSK, said: “We are excited about ... life stage when they are at an increased risk.” Judy Klein, President and Founder of Unity Consortium, a non ...
LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...
Feb 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and ...
Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...
Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback